Factors affecting pharmacokinetic variability following doxorubicin and docetaxel-based therapy.

[1]  Lewis B. Sheiner,et al.  A population pharmacokinetic model for docetaxel (Taxotere®): Model building and validation , 1996, Journal of Pharmacokinetics and Biopharmaceutics.

[2]  Mark J. Ratain,et al.  Body Surface Area as a Determinant of Pharmacokinetics and Drug Dosing , 2001, Investigational New Drugs.

[3]  René Bruno,et al.  Population Pharmacokinetics and Pharmacokinetic-Pharmacodynamic Relationships for Docetaxel , 2001, Investigational New Drugs.

[4]  R. Erttmann,et al.  Pharmacokinetics of doxorubicin in man: dose and schedule dependence , 2004, Journal of Cancer Research and Clinical Oncology.

[5]  S. B. Lucas,et al.  Comparative pharmacokinetics of escalating doses of doxorubicin in patients with metastatic breast cancer , 2004, Cancer Chemotherapy and Pharmacology.

[6]  I. Näslund,et al.  Pharmacokinetic study of IV infusions of adriamycin , 2004, European Journal of Clinical Pharmacology.

[7]  P. Gwilt,et al.  The effect of age on the early disposition of doxorubicin , 2003, Cancer Chemotherapy and Pharmacology.

[8]  M. Egorin.  Horseshoes, hand grenades, and body-surface area-based dosing: aiming for a target. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  L. Grochow,et al.  Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001. , 2002, Journal of the National Cancer Institute.

[10]  Antonius A. Miller.  Body surface area in dosing anticancer agents: scratch the surface! , 2002, Journal of the National Cancer Institute.

[11]  J Verweij,et al.  Dosing strategies for anticancer drugs: the good, the bad and body-surface area. , 2002, European journal of cancer.

[12]  J. Verweij,et al.  Disposition of docetaxel in the presence of P-glycoprotein inhibition by intravenous administration of R101933. , 2002, European journal of cancer.

[13]  H. Gurney,et al.  How to calculate the dose of chemotherapy , 2002, British Journal of Cancer.

[14]  J. Verweij,et al.  Phase I pharmacokinetic and sequence finding study of the combination of docetaxel and methotrexate in patients with solid tumours. , 2002, European journal of cancer.

[15]  R. Danesi,et al.  Pharmacokinetic-Pharmacodynamic Relationships of the Anthracycline Anticancer Drugs , 2002, Clinical pharmacokinetics.

[16]  J. Schellens,et al.  Pharmacokinetically Guided Administration of Chemotherapeutic Agents , 2000, Clinical pharmacokinetics.

[17]  B. Reigner,et al.  A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours , 2000, British Journal of Cancer.

[18]  J. Verweij,et al.  The orally administered P-glycoprotein inhibitor R101933 does not alter the plasma pharmacokinetics of docetaxel. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[19]  S. Goodman,et al.  A Prospective Pharmacologic Evaluation of Age-Related Toxicity of Adjuvant Chemotherapy in Women with Breast Cancer , 2000, Cancer investigation.

[20]  J Verweij,et al.  Clinical pharmacokinetics of doxorubicin in combination with GF120918, a potent inhibitor of MDR1 P-glycoprotein. , 1999, Anti-cancer drugs.

[21]  F. Appelbaum,et al.  The impact of obesity and disease on busulfan oral clearance in adults. , 1999, Blood.

[22]  J. Verweij,et al.  Determination of doxorubicin and doxorubicinol in plasma of cancer patients by high-performance liquid chromatography. , 1999, Analytical Biochemistry.

[23]  M. Ratain.  Body-surface area as a basis for dosing of anticancer agents: science, myth, or habit? , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  M. Relling,et al.  Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. , 1998, The New England journal of medicine.

[25]  L. Grochow,et al.  A clinician's guide to chemotherapy pharmacokinetics and pharmacodynamics , 1998 .

[26]  L B Sheiner,et al.  Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  J. Verweij,et al.  Sensitive determination of docetaxel in human plasma by liquid-liquid extraction and reversed-phase high-performance liquid chromatography. , 1997, Journal of chromatography. B, Biomedical sciences and applications.

[28]  G. Bonadonna,et al.  Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  M. J. van den Bent,et al.  Phase I and pharmacologic study of docetaxel and cisplatin in patients with advanced solid tumors. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  O Pelkonen,et al.  Age and cytochrome P450‐linked drug metabolism in humans: An analysis of 226 subjects with equal histopathologic conditions , 1997, Clinical pharmacology and therapeutics.

[31]  H. Gurney,et al.  Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  L. Grochow,et al.  Should anticancer drug doses be adjusted in the obese patient? , 1995, Journal of the National Cancer Institute.

[33]  J. Zalcberg,et al.  Lean body mass, body surface area and epirubicin kinetics. , 1994, Anti-cancer drugs.

[34]  D. Morgan,et al.  Lean Body Mass as a Predictor of Drug Dosage , 1994, Clinical pharmacokinetics.

[35]  L. Grochow,et al.  Is dose normalization to weight or body surface area useful in adults? , 1990, Journal of the National Cancer Institute.

[36]  E Wiltshaw,et al.  Carboplatin dosage: prospective evaluation of a simple formula based on renal function. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  D. Rushing,et al.  Doxorubicin clearance in the obese. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  O. Colvin,et al.  Interactions between cyclophosphamide and adriamycin metabolism in rats. , 1984, The Journal of pharmacology and experimental therapeutics.

[39]  A Schumitzky,et al.  A program package for simulation and parameter estimation in pharmacokinetic systems. , 1979, Computer programs in biomedicine.

[40]  D. DuBois,et al.  A formula to estimate the approximate surface area if height and weight be known , 1989 .

[41]  D. D. Bois,et al.  CLINICAL CALORIMETRY: TENTH PAPER A FORMULA TO ESTIMATE THE APPROXIMATE SURFACE AREA IF HEIGHT AND WEIGHT BE KNOWN , 1916 .